Postprandial hypertriglyceridemia as a coronary risk factor

Clinica Chimica Acta

Volumn 431, Issue , 2014, Pages 131-142

  Borén, Jan ^a   Matikainen, Niina ^b,c   Adiels, Martin ^a   Taskinen, Marja Riitta ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b HUCH Heart and Lung Centre   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cardiovascular risk factor; Postprandial hypertriglyceridemia; Triglyceride rich lipoproteins

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B48; APOLIPOPROTEIN C3; CHOLESTEROL; CHYLOMICRON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CASE MANAGEMENT; CORONARY RISK; DISEASE MARKER; EPIDEMIOLOGICAL DATA; EVIDENCE BASED PRACTICE; FAT INTAKE; FAT TOLERANCE TEST; GENETIC VARIABILITY; HORMONAL THERAPY; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOPROTEIN SECRETION; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; BLOOD; CORONARY ARTERY DISEASE; RISK FACTOR;

CORONARY DISEASE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; POSTPRANDIAL PERIOD; RISK FACTORS; TRIGLYCERIDES;

EID: 84896740238     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.01.015     Document Type: Review

References (187)

1. Chapman M.J., Ginsberg H.N., Amarenco P., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32:1345-1361.
2. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
3. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
4. Freiberg J.J., Tybjaerg-Hansen A., Jensen J.S., Nordestgaard B.G. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008, 300:2142-2152.
5. Dallinga-Thie G.M., Franssen R., Mooij H.L., et al. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis 2010, 211:1-8.
6. Zilversmit D.B. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ Res 1973, 33:633-638.
7. Moreton J.R. Atherosclerosis and alimentary hyperlipidemia. Science 1947, 106:190-191.
8. Cohn J.S., Johnson E.J., Millar J.S., et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 1993, 34:2033-2040.
9. Nakajima K., Nakano T., Tokita Y., et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta Int J Clin Chem 2011, 412:1306-1318.
10. Olofsson S.O., Wiklund O., Boren J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag 2007, 3:491-502.
11. Olofsson S.O., Boren J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 2005, 258:395-410.
12. Karpe F., Bell M., Bjorkegren J., Hamsten A. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol 1995, 15:199-207.
13. Schneeman B.O., Kotite L., Todd K.M., Havel R.J. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci U S A 1993, 90:2069-2073.
14. Brunzell J.D., Hazzard W.R., Porte D., Bierman E.L. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 1973, 52:1578-1585.
15. Adiels M., Matikainen N., Westerbacka J., et al. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis 2012, 222:222-228.
16. Boren J., Taskinen M.R., Olofsson S.O., Levin M. Ectopic lipid storage and insulin resistance: a harmful relationship. J Intern Med 2013, 274:25-40.
17. Olofsson S.O., Boren J. Apolipoprotein B secretory regulation by degradation. Arterioscler Thromb Vasc Biol 2012, 32:1334-1338.
18. Abumrad N.A., Davidson N.O. Role of the gut in lipid homeostasis. Physiol Rev 2012, 92:1061-1085.
19. Lambert J.E., Parks E.J. Postprandial metabolism of meal triglyceride in humans. Biochim Biophys Acta 1821, 2012:721-726.
20. Xiao C., Lewis G.F. Regulation of chylomicron production in humans. Biochim Biophys Acta 1821, 2012:736-746.
21. Ramasamy I. Recent advances in physiological lipoprotein metabolism. Clin Chem Lab Med 2013, 1-33.
22. Mattes R.D. Oral fat exposure increases the first phase triacylglycerol concentration due to release of stored lipid in humans. J Nutr 2002, 132:3656-3662.
23. Robertson M.D., Henderson R.A., Vist G.E., Rumsey R.D. Extended effects of evening meal carbohydrate-to-fat ratio on fasting and postprandial substrate metabolism. Am J Clin Nutr 2002, 75:505-510.
24. Chavez-Jauregui R.N., Mattes R.D., Parks E.J. Dynamics of fat absorption and effect of sham feeding on postprandial lipema. Gastroenterology 2010, 139:1538-1548.
25. Hiraoka T., Fukuwatari T., Imaizumi M., Fushiki T. Effects of oral stimulation with fats on the cephalic phase of pancreatic enzyme secretion in esophagostomized rats. Physiol Behav 2003, 79:713-717.
26. Mattes R.D. Is there a fatty acid taste?. Annu Rev Nutr 2009, 29:305-327.
27. Ahren B., Holst J.J. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes 2001, 50:1030-1038.
28. Teff K.L., Engelman K. Oral sensory stimulation improves glucose tolerance in humans: effects on insulin, C-peptide, and glucagon. Am J Physiol 1996, 270:R1371-R1379.
29. Mattes R.D. Brief oral stimulation, but especially oral fat exposure, elevates serum triglycerides in humans. Am J Physiol Gastrointest Liver Physiol 2009, 296:G365-G371.
30. Robertson M.D., Parkes M., Warren B.F., et al. Mobilisation of enterocyte fat stores by oral glucose in humans. Gut 2003, 52:834-839.
31. Khan N.A., Besnard P. Oro-sensory perception of dietary lipids: new insights into the fat taste transduction. Biochim Biophys Acta 2009, 1791:149-155.
32. Adiels M., Olofsson S.O., Taskinen M.R., Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.
33. Adiels M., Westerbacka J., Soro-Paavonen A., et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007, 50:2356-2365.
34. Adiels M., Taskinen M.R., Packard C., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006, 49:755-765.
35. Adiels M., Olofsson S.O., Taskinen M.R., Boren J. Diabetic dyslipidaemia. Curr Opin Lipidol 2006, 17:238-246.
36. Adiels M., Packard C., Caslake M.J., et al. A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res 2005, 46:58-67.
37. Adiels M., Boren J., Caslake M.J., et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005, 25:1697-1703.
38. Haas M.E., Attie A.D., Biddinger S.B. The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab 2013, 24:391-397.
39. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009, 48:1-26.
40. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010, 53:372-384.
41. Kissebah A.H., Alfarsi S., Evans D.J., Adams P.W. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 1982, 31:217-225.
42. Duvillard L., Pont F., Florentin E., Galland-Jos C., Gambert P., Verges B. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest 2000, 30:685-694.
43. Ouguerram K., Magot T., Zair Y., et al. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J Pharmacol Exp Ther 2003, 306:332-337.
44. Cummings M.H., Watts G.F., Umpleby A.M., et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 1995, 38:959-967.
45. Sparks J.D., Sparks C.E., Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2012, 32:2104-2112.
46. Kamagate A., Dong H.H. FoxO1 integrates insulin signaling to VLDL production. Cell Cycle 2008, 7:3162-3170.
47. Wan M., Leavens K.F., Saleh D., et al. Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c. Cell Metab 2011, 14:516-527.
48. Leavens K.F., Birnbaum M.J. Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol 2011, 46:200-215.
49. Kamagate A., Qu S., Perdomo G., et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 2008, 118:2347-2364.
50. Ai D., Baez J.M., Jiang H., et al. Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. J Clin Invest 2012, 122:1677-1687.
51. Strong A., Ding Q., Edmondson A.C., et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest 2012, 122:2807-2816.
52. Strong A., Rader D.J. Sortilin as a regulator of lipoprotein metabolism. Curr Atheroscler Rep 2012, 14:211-218.
53. Andersson L., Bostrom P., Ericson J., et al. PLD1 and ERK2 regulate cytosolic lipid droplet formation. J Cell Sci 2006, 119:2246-2257.
54. Holst J.J., Vilsboll T., Deacon C.F. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009, 297:127-136.
55. Van Gaal L.F., Gutkin S.W., Nauck M.A. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?. Eur J Endocrinol 2008, 158:773-784.
56. Ussher J.R., Drucker D.J. Cardiovascular biology of the incretin system. Endocr Rev 2012, 33:187-215.
57. Xiao C., Hsieh J., Adeli K., Lewis G.F. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am J Physiol Endocrinol Metab 2011, 301:E429-E446.
58. Hsieh J., Longuet C., Baker C.L., et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010, 53:552-561.
59. Xiao C., Bandsma R.H., Dash S., Szeto L., Lewis G.F. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol 2012, 32:1513-1519.
60. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
61. Hsieh J., Longuet C., Maida A., et al. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology 2009, 137:997-1005. 1005 e1001-1004.
62. Goldberg I.J. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996, 37:693-707.
63. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
64. Marcoux C., Tremblay M., Fredenrich A., Davignon J., Cohn J.S. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Metabolism 2001, 50:112-119.
65. Sacks F.M., Alaupovic P., Moye L.A., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 2000, 102:1886-1892.
66. Lee S.J., Campos H., Moye L.A., Sacks F.M. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003, 23:853-858.
67. Pollin T.I., Damcott C.M., Shen H., et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008, 322:1702-1705.
68. Chen M., Breslow J.L., Li W., Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res 1994, 35:1918-1924.
69. Altomonte J., Cong L., Harbaran S., et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 2004, 114:1493-1503.
70. Hertz R., Bishara-Shieban J., Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995, 270:13470-13475.
71. Claudel T., Inoue Y., Barbier O., et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003, 125:544-555.
72. Caron S., Verrijken A., Mertens I., et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2011, 31(3):513-519.
73. Ginsberg H.N., Brown W.V. Apolipoprotein CIII: 42years old and even more interesting. Arterioscler Thromb Vasc Biol 2011, 31:471-473.
74. Hiukka A., Stahlman M., Pettersson C., et al. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 2009, 58:2018-2026.
75. Lee S.J., Moye L.A., Campos H., Williams G.H., Sacks F.M. Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis 2003, 167:293-302.
76. Hiukka A., Fruchart-Najib J., Leinonen E., Hilden H., Fruchart J.C., Taskinen M.R. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia 2005, 48:1207-1215.
77. Williams K.J., Chen K. Recent insights into factors affecting remnant lipoprotein uptake. Curr Opin Lipidol 2010, 21:218-228.
78. Williams K.J. Molecular processes that handle - and mishandle - dietary lipids. J Clin Invest 2008, 118:3247-3259.
79. Mahley R.W., Ji Z.S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999, 40:1-16.
80. MacArthur J.M., Bishop J.R., Stanford K.I., et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest 2007, 117:153-164.
81. Williams K.J., Fless G.M., Petrie K.A., Snyder M.L., Brocia R.W., Swenson T.L. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem 1992, 267:13284-13292.
82. Fuki I.V., Kuhn K.M., Lomazov I.R., et al. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest 1997, 100:1611-1622.
83. Chen K., Liu M.L., Schaffer L., et al. Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins. Hepatology 2010, 52:1957-1967.
84. Hassing H.C., Mooij H., Guo S., et al. Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia. Hepatology 2012, 55:1746-1753.
85. Hassing C., Mooij H., Dallinga-Thie G., et al. Genetic variation in SULF2 is associated with plasma triglyceride levels in subjects with type 2 diabetes. XVI International Symposium on Atherosclerosis - ISA2012. Sydney 2012.
86. Matikainen N., Burza M.A., Romeo S., et al. Genetic variation in SULF2 is associated with postprandial clearance of triglyceride-rich remnant particles and triglyceride levels in healthy subjects. PLoS One 2013, 8:e79473.
87. Riches F.M., Watts G.F., Naoumova R.P., Kelly J.M., Croft K.D., Thompson G.R. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord J Int Assoc Study Obes 1998, 22:414-423.
88. Chan D.C., Watts G.F., Redgrave T.G., Mori T.A., Barrett P.H. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 2002, 51:1041-1046.
89. Watts G.F., Barrett P.H., Ji J., et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003, 52:803-811.
90. Bjorkegren J., Packard C.J., Hamsten A., et al. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res 1996, 37:76-86.
91. van Beek A.P., van Barlingen H.H., de Ruijter-Heijstek F.C., et al. Preferential clearance of apoB-48-containing lipoproteins after heparin-induced lipolysis is modulated by lipoprotein lipase activity. J Lipid Res 1998, 39:322-332.
92. Miller M., Stone N.J., Ballantyne C., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333.
93. Brahm A., Hegele R.A. Hypertriglyceridemia. Nutrient 2013, 5:981-1001.
94. Lopez-Miranda J., Williams C., Lairon D. Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. Br J Nutr 2007, 98:458-473.
95. Jackson K.G., Poppitt S.D., Minihane A.M. Postprandial lipemia and cardiovascular disease risk: interrelationships between dietary, physiological and genetic determinants. Atherosclerosis 2012, 220:22-33.
96. Perez-Martinez P., Delgado-Lista J., Perez-Jimenez F., Lopez-Miranda J. Update on genetics of postprandial lipemia. Atheroscler Suppl 2010, 11:39-43.
97. Varbo A., Benn M., Tybjaerg-Hansen A., Jorgensen A.B., Frikke-Schmidt R., Nordestgaard B.G. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013, 61:427-436.
98. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 1979, 60:473-485.
99. Proctor S.D., Vine D.F., Mamo J.C. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol 2002, 13:461-470.
100. Brunzell J.D. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. The metabolic and molecular bases of inherited disease 1995, 1913-1932. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
101. Benlian P., De Gennes J.L., Foubert L., Zhang H., Gagne S.E., Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996, 335:848-854.
102. Neil H.A., Cooper J., Betteridge D.J., et al. All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: a long-term prospective registry study. Atherosclerosis 2010, 211:618-623.
103. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724-730.
104. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyorala K., Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009, 16:121-137.
105. Eriksson M., Zethelius B., Eeg-Olofsson K., et al. Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register. Eur J Cardiovasc Prev Rehabil 2011, 18:97-105.
106. Assmann G., Cullen P., Schulte H. Non-LDL-related dyslipidaemia and coronary risk: a case-control study. Diab Vasc Dis Res 2010, 7:204-212.
107. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
108. Sarwar N., Danesh J., Eiriksdottir G., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
109. Di Angelantonio E., Sarwar N., Perry P., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
110. Patel A., Barzi F., Jamrozik K., et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004, 110:2678-2686.
111. Lindman A.S., Veierod M.B., Tverdal A., Pedersen J.I., Selmer R. Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian counties study. Eur J Epidemiol 2010, 25:789-798.
112. Langsted A., Freiberg J.J., Tybjaerg-Hansen A., Schnohr P., Jensen G.B., Nordestgaard B.G. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart study with 31years of follow-up. J Intern Med 2011, 270:65-75.
113. Varbo A., Nordestgaard B.G., Tybjaerg-Hansen A., Schnohr P., Jensen G.B., Benn M. Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population. Ann Neurol 2011, 69:628-634.
114. Langsted A., Freiberg J.J., Nordestgaard B.G. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008, 118:2047-2056.
115. Nakajima K., Saito T., Tamura A., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta Int J Clin Chem 1993, 223:53-71.
116. Fujioka Y., Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 2009, 16:145-154.
117. McNamara J.R., Shah P.K., Nakajima K., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart study. Atherosclerosis 2001, 154:229-236.
118. Kugiyama K., Doi H., Takazoe K., et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999, 99:2858-2860.
119. Imke C., Rodriguez B.L., Grove J.S., et al. Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study. Arterioscler Thromb Vasc Biol 2005, 25:1718-1722.
120. Karpe F., Boquist S., Tang R., Bond G.M., de Faire U., Hamsten A. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 2001, 42:17-21.
121. Patsch J.R., Miesenbock G., Hopferwieser T., et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992, 12:1336-1345.
122. Enkhmaa B., Ozturk Z., Anuurad E., Berglund L. Postprandial lipoproteins and cardiovascular disease risk in diabetes mellitus. Curr Diabetes Rep 2010, 10:61-69.
123. Masuda D., Sugimoto T., Tsujii K., et al. Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur J Clin Invest 2012, 42:992-999.
124. Mori K., Ishida T., Yasuda T., et al. Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease. Clin Chim Acta Int J Clin Chem 2013, 421:51-56.
125. Langsted A., Nordestgaard B.G. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population study. Clin Chem 2011, 57:482-489.
126. Smith S.J., Cooper G.R., Myers G.L., Sampson E.J. Biological variability in concentrations of serum lipids: sources of variation among results from published studies and composite predicted values. Clin Chem 1993, 39:1012-1022.
127. Klop B., Cohn J.S., van Oostrom A.J., van Wijk J.P., Birnie E., Castro Cabezas M. Daytime triglyceride variability in men and women with different levels of triglyceridemia. Clin Chim Acta Int J Clin Chem 2011, 412:2183-2189.
128. Cohn J.S., McNamara J.R., Cohn S.D., Ordovas J.M., Schaefer E.J. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res 1988, 29:925-936.
129. Kolovou G.D., Mikhailidis D.P., Kovar J., et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011, 9:258-270.
130. Ooi T.C., Nordestgaard B.G. Methods to study postprandial lipemia. Curr Vasc Pharmacol 2011, 9:302-308.
131. Mihas C., Kolovou G.D., Mikhailidis D.P., et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol 2011, 9:271-280.
132. Dominiczak M.H., Caslake M.J. Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem 2011, 48:498-515.
133. Nakano T., Tokita Y., Nagamine T., et al. Measurement of serum remnant-like lipoprotein particle-triglyceride (RLP-TG) and RLP-TG/total TG ratio using highly sensitive triglyceride assay reagent. Clin Chim Acta Int J Clin Chem 2011, 412:71-78.
134. Nakajima K., Nakano T., Moon H.D., et al. The correlation between TG vs remnant lipoproteins in the fasting and postprandial plasma of 23 volunteers. Clin Chim Acta Int J Clin Chem 2009, 404:124-127.
135. Nakajima K., Nakano T., Tokita Y., et al. The characteristics of remnant lipoproteins in the fasting and postprandial plasma. Clin Chim Acta Int J Clin Chem 2012, 413:1077-1086.
136. Nakamura T., Obata J.E., Hirano M., et al. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis 2011, 218:163-167.
137. Miyauchi K., Kayahara N., Ishigami M., et al. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem 2007, 53:2128-2135.
138. Yoshida H., Kurosawa H., Hirowatari Y., et al. Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C). Lipids Health Dis 2008, 7:18.
139. Schaefer E.J. Limitations of automated remnant lipoprotein cholesterol assay for diagnostic use. Clin Chem 2009, 55:2061-2062. author reply 2062-2063.
140. Phillips M.L., Pullinger C., Kroes I., et al. A single copy of apolipoprotein B-48 is present on the human chylomicron remnant. J Lipid Res 1997, 38:1170-1177.
141. Smith D., Watts G.F., Dane-Stewart C., Mamo J.C. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest 1999, 29:204-209.
142. Kotite L., Bergeron N., Havel R.J. Quantification of apolipoproteins B-100, B-48, and E in human triglyceride-rich lipoproteins. J Lipid Res 1995, 36:890-900.
143. Karpe F., Hamsten A. Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J Lipid Res 1994, 35:1311-1317.
144. Smith D., Proctor S.D., Mamo J.C. A highly sensitive assay for quantitation of apolipoprotein B48 using an antibody to human apolipoprotein B and enhanced chemiluminescence. Ann Clin Biochem 1997, 34(Pt 2):185-189.
145. Sakai N., Uchida Y., Ohashi K., et al. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 2003, 44:1256-1262.
146. Kinoshita M., Kojima M., Matsushima T., Teramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta Int J Clin Chem 2005, 351:115-120.
147. Jackson K.G., Williams C.M. Apolipoprotein B-48: comparison of fasting concentrations measured in normolipidaemic individuals using SDS-PAGE, immunoblotting and ELISA. Atherosclerosis 2004, 176:207-217.
148. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
149. Berglund L., Brunzell J.D., Goldberg A.C., et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012, 97:2969-2989.
150. Watts G.F., Ooi E.M., Chan D.C. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol 2013, 10:648-661.
151. Chan D.C., Pang J., Romic G., Watts G.F. Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. Curr Atheroscler Rep 2013, 15:309.
152. Ryden L., Grant P.J., Anker S.D., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013, 34:3035-3087.
153. Schaefer E.J., McNamara J.R., Tayler T., et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 2004, 93:31-39.
154. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
155. HPS2-THRIVE randomized placebo-controlled trial in 25673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34:1279-1291.
156. Song W.L., FitzGerald G.A. Niacin, an old drug with a new twist. J Lipid Res 2013, 54:2586-2594.
157. Rizos E.C., Ntzani E.E., Bika E., Kostapanos M.S., Elisaf M.S. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012, 308:1024-1033.
158. Jump D.B., Depner C.M., Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. J Lipid Res 2012, 53:2525-2545.
159. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
160. Scott R., O'Brien R., Fulcher G., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498.
161. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
162. Chan D.C., Wong A.T., Yamashita S., Watts G.F. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment. Atherosclerosis 2012, 221:484-489.
163. Reyes-Soffer G., Ngai C.I., Lovato L., et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care 2013, 36:422-428.
164. Bozzetto L., Annuzzi G., Corte G.D., et al. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 2011, 217:142-148.
165. Hajer G.R., Dallinga-Thie G.M., van Vark-van der Zee L.C., Visseren F.L. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 2009, 202:216-224.
166. Kikuchi K., Nezu U., Inazumi K., et al. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J Atheroscler Thromb 2012, 19:1093-1101.
167. Tremblay A.J., Lamarche B., Hogue J.C., Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J Lipid Res 2009, 50:1463-1471.
168. Phillips L.K., Prins J.B. Update on incretin hormones. Ann N Y Acad Sci 2011, 1243:E55-E74.
169. Holst J.J., Orskov C. Incretin hormones - an update. Scand J Clin Lab Invest Suppl 2001, 234:75-85.
170. Hein G.J., Baker C., Hsieh J., Farr S., Adeli K. GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes 2013, 62:373-381.
171. Matikainen N., Manttari S., Schweizer A., et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006, 49:2049-2057.
172. Bunck M.C., Corner A., Eliasson B., et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010, 212:223-229.
173. Tremblay A.J., Lamarche B., Deacon C.F., Weisnagel S.J., Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011, 13:366-373.
174. Eliasson B., Moller-Goede D., Eeg-Olofsson K., et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 2012, 55:915-925.
175. Farr S., Adeli K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr Opin Lipidol 2012, 23:56-61.
176. Huff M.W., Hegele R.A. Apolipoprotein C-III: going back to the future for a lipid drug target. Circ Res 2013, 112:1405-1408.
177. Kaeppel C., Beattie S.G., Fronza R., et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med 2013, 19:889-891.
178. Haddley K. Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc.) 2013, 49:161-170.
179. Burnett J.R., Hooper A.J. Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. Curr Opin Mol Ther 2009, 11:681-691.
180. Carpentier A.C., Frisch F., Labbe S.M., et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab 2012, 97:1635-1644.
181. Gaudet D., Methot J., Dery S., et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 2013, 20:361-369.
182. Graham M.J., Lee R.G., Bell T.A., et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013, 112:1479-1490.
183. Panel E.A.S.C. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis and management. Lancet Diabetes Endocrinol 2013, [in press]. 10.1016/S2213-8587(13)70191-8.
184. Skalen K., Gustafsson M., Rydberg E.K., et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
185. Tabas I., Williams K.J., Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
186. Varbo A., Benn M., Nordestgaard B.G. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther Mar. 2014, 141(3):358-367.
187. Flood C., Gustafsson M., Pitas R.E., Arnaboldi L., Walzem R.L., Boren J. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. Arterioscler Thromb Vasc Biol 2004, 24:564-570.